PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
23-Aug-2022 Global Epilepsy Therapeutics Market worth US$16.6 billion by 2031: Visiongain Reports Ltd Visiongain Reports Limited
23-Aug-2022 Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy Santhera
23-Aug-2022 Global Fill Finish Manufacturing Market is projected to grow at a CAGR of 9.0% By 2031: Visiongain Reports Ltd Visiongain Reports Limited
18-Aug-2022 NEW CLINICAL TRIALS INITIATIVE LAUNCHED TO SUPPORT MEDTECH COMPANIES Empact Ventures
16-Aug-2022 Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral Pneumagen
15-Aug-2022 R&G Pharmastudies Listed on the ChiNext Market Successfully Legend Capital
12-Aug-2022 Point of Care Diagnostic Market Worth $73,293 Million by 2031: Visiongain Reports Ltd Visiongain Reports Limited
11-Aug-2022 Aqilion starts Phase 1 clinical trial with drug candidate AQ280 for chronic inflammatory diseases AQILION AB
10-Aug-2022 Global CNS Therapeutics Market Forecast is expected to reach US$ 133.2 billion in 2026 Visiongain Reports Limited
09-Aug-2022 The Global Biologics market is projected to grow at a CAGR of 8.82% By 2032: Visiongain Reports Ltd Visiongain Reports Limited
09-Aug-2022 Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia Karuna Therapeutics
09-Aug-2022 HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial HUTCHMED
09-Aug-2022 U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) Orion
09-Aug-2022 HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer HUTCHMED
09-Aug-2022 EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer EQRx
08-Aug-2022 Global Drug Discovery Services market is projected to grow at a CAGR of 15.17% by 2032; Visiongain Reports Ltd Visiongain Reports Limited
08-Aug-2022 Global Genome Editing Technologies market is projected to grow at a CAGR of 15.96% by 2032: Visiongain Reports Ltd Visiongain Reports Limited
08-Aug-2022 Oncology Applications of Epigenetics in Healthcare Offering Treatment to Cancer P&S Intelligence
03-Aug-2022 Speaker Interview with Macarena Hernandez- Jimenez released for Oligonucleotide Therapeutics & Delivery Conference 2022 SAE Media Group
02-Aug-2022 Shionogi Begins Phase 3 Study in Japan of Akili’s Digital Treatment in Children with ADHD Shionogi